Showing 4851-4860 of 5331 results for "".
- Novan's Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugshttps://practicaldermatology.com/news/20140820-novans_nitricil_technology_shows_efficacy_against_multidrug_resistant_superbugs/2459140/Novan Therapeutics' Nitricil™ platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe, according to new data. The
- Carma Laboratories Introduces New Carmex® Cold Sore Treatmenthttps://practicaldermatology.com/news/20140820-carma_laboratories_introduces_new_carmex_cold_sore_treatment/2459142/Carma Laboratories, Inc., the maker of Carmex® lip balm products, has launched the new Carmex® Cold Sore Treatment. This product features TriPLEX™ Formula advanced technology, which combines three different optical brightener and filler technologies that each provide unique appea
- Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, And Sinopharm A-Think Pharmaceutical Co., LTDhttps://practicaldermatology.com/news/20140818-provectus_signs_memorandum_of_understanding_with_sinopharm-china_state_institute_of_pharmaceutical_industry_and_sinopharm_a-think_pharmaceutical_co_lt/2459143/Negotiations on Licensing PV-10 in China Opened Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it entered into a Memorandum of Understanding (“MOU”) with
- Syneron Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosishttps://practicaldermatology.com/news/20140815-syneron_introduces_new_fda-cleared_5mm_spot_size_for_treatment_of_onychomycosis/2459145/Syneron Medical Ltd. launched a new handpiece featuring a new 5-millimeter spot size for the Gentle Pro Nd:YAG Laser Series. The introduction of this new FDA-cleared handp
- Lithera Changes Name to Neothetics, Inc.https://practicaldermatology.com/news/20140812-lithera_changes_name_to_neothetics_inc/2459146/In a move the company says is intended to stregthen its positioning as a clinical stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market, Lithera has changed its name to Neothetics, Inc. President and CEO of Neothetics George Mahaffey said, "Our ne
- Editorial: Transferrable Loyalty and the State of Our Specialtyhttps://practicaldermatology.com/news/20140806-editorial_transferrable_loyalty_and_the_state_of_our_specialty/2459149/With the ongoing battle between Allergan and Valeant, it is evident that no practicing dermatologist can avoid concerns with the painful and tactical machinations. Long-term representatives have likely already changed their nametags from one company to another and are now pitching the same drugs und
- FDA Warns of Adverse Events Associated with Unapproved Use of Expression Injectable as a Dermal Fillerhttps://practicaldermatology.com/news/20140806-fda_warns_of_adverse_events_associated_with_unapproved_use_of_expression_injectable_as_a_dermal_filler/2459150/The FDA reported that it has become aware of adverse events associated with the unapproved use of the Expression product, hyaluronic acid that is packaged in a syringe, as a dermal filler. Events have included swelling, tenderness, firmness, lumps, bu
- National Call-to-Action on Skin Cancer Preventionhttps://practicaldermatology.com/news/20140806-national_call-to-action_on_skin_cancer_prevention/2459152/The American Academy of Dermatology Association (AADA) recently joined with the U.S. Department of Health and Human Services' (HHS) Office of the Surgeon General and Centers for Disease Control and Prevention (CDC) to issue a national call-to-action on skin cancer prevention. T
- Cynosure's PicoSure Laser Cleared by FDA for Acne Scarshttps://practicaldermatology.com/news/20140801-cynosure_announces_picosure_is_fda-cleared_to_treat_acne_scars/2459153/The FDA cleared the PicoSure picosecond laser to treat acne scars. "We are thrilled to announce that PicoSure, the world's most advanced laser technology for tattoo removal and benign pigmented lesions, has now received FDA-clearance to treat acne scar
- FDA Approves of Acticlate Tablets from Aqua Pharmaceuticals, LLChttps://practicaldermatology.com/news/20140728-aqua_pharmaceuticals_llc_announces_fda_approval_of_acticlate_tablets/2459155/The FDA approved Aqua Pharmaceuticals' Acticlate (doxycycline hyclate USP) Tablets, 150 mg and 75 mg, an oral antibiotics for acne. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.